Literature DB >> 24211139

Poor survival in prostate cancer patients with primary refractoriness to docetaxel.

Giuseppe Di Lorenzo1, Sergio Bracarda2, Carlo Buonerba3, Michele Aieta4, Vincenzo Mirone5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24211139     DOI： 10.1016/j.eururo.2013.10.037

Source DB:  PubMed          Journal:  Eur Urol        ISSN： 0302-2838            Impact factor:   20.096


× No keyword cloud information.
  9 in total

Review 1.  The Evolving Systemic Treatment Landscape for Patients with Advanced Prostate Cancer.

Authors:  Martina Pagliuca; Carlo Buonerba; Karim Fizazi; Giuseppe Di Lorenzo
Journal:  Drugs       Date:  2019-03       Impact factor: 9.546

2.  Circ_0004087 interaction with SND1 promotes docetaxel resistance in prostate cancer by boosting the mitosis error correction mechanism.

Authors:  Liang Chen; Yarong Song; Teng Hou; Xuexiang Li; Lulin Cheng; Yunxue Li; Yifei Xing
Journal:  J Exp Clin Cancer Res       Date:  2022-06-03

Review 3.  Docetaxel Rechallenge in a Heavily Pretreated Patient With Castration-Resistant Prostate Cancer: A Case Report and Review of Literature.

Authors:  Giuseppe Di Lorenzo; Martina Pagliuca; Teresa Perillo; Alfonso Benincasa; Davide Bosso; Sabino De Placido; Carlo Buonerba
Journal:  Medicine (Baltimore)       Date:  2016-04       Impact factor: 1.889

4.  The Influence of Prednisone on the Efficacy of Cabazitaxel in Men with Metastatic Castration-Resistant Prostate Cancer.

Authors:  Carlo Buonerba; Guru Sonpavde; Francesca Vitrone; Davide Bosso; Livio Puglia; Michela Izzo; Simona Iaccarino; Luca Scafuri; Margherita Muratore; Francesca Foschini; Brigitta Mucci; Vincenzo Tortora; Martina Pagliuca; Dario Ribera; Vittorio Riccio; Rocco Morra; Mirta Mosca; Nicola Cesarano; Ileana Di Costanzo; Sabino De Placido; Giuseppe Di Lorenzo
Journal:  J Cancer       Date:  2017-08-22       Impact factor: 4.207

5.  Targeting AXL overcomes resistance to docetaxel therapy in advanced prostate cancer.

Authors:  Jian-Zhong Lin; Zeng-Jun Wang; Wei De; Ming Zheng; Wei-Zhang Xu; Hong-Fei Wu; Alex Armstrong; Jia-Geng Zhu
Journal:  Oncotarget       Date:  2017-06-20

6.  Real-world experience with cabazitaxel in patients with metastatic castration-resistant prostate cancer: a final, pooled analysis of the compassionate use programme and early access programme.

Authors:  Zafar Malik; Axel Heidenreich; Sergio Bracarda; Alexandros Ardavanis; Philip Parente; Hans-Joerg Scholz; Ayse Ozatilgan; Evelyne Ecstein-Fraisse; Simon Hitier; Giuseppe Di Lorenzo
Journal:  Oncotarget       Date:  2019-06-25

7.  CNTN-1 promotes docetaxel resistance and epithelial-to-mesenchymal transition via the PI3K/Akt signaling pathway in prostate cancer.

Authors:  Binshen Chen; Yiming Zhang; Chaoming Li; Peng Xu; Yubo Gao; Yawen Xu
Journal:  Arch Med Sci       Date:  2020-02-12       Impact factor: 3.318

8.  Cholesterol biosynthesis inhibitor RO 48-8071 suppresses growth of hormone-dependent and castration-resistant prostate cancer cells.

Authors:  Yayun Liang; Benford Mafuvadze; Johannes D Aebi; Salman M Hyder
Journal:  Onco Targets Ther       Date:  2016-05-30       Impact factor: 4.147

9.  Lack of Cumulative Toxicity Associated With Cabazitaxel Use in Prostate Cancer.

Authors:  Giuseppe Di Lorenzo; Sergio Bracarda; Donatello Gasparro; Angela Gernone; Caterina Messina; Vittorina Zagonel; Livio Puglia; Davide Bosso; Davide Dondi; Guru Sonpavde; Giuseppe Lucarelli; Sabino De Placido; Carlo Buonerba
Journal:  Medicine (Baltimore)       Date:  2016-01       Impact factor: 1.817
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.